Executive Overview
Revolutionary immunotherapies such as Chimeric Antigen Receptor (CAR) T-cell therapy and T-cell engaging bispecific antibodies (BsAbs) have fundamentally altered the...
Revolutionary immunotherapies such as Chimeric Antigen Receptor (CAR) T-cell therapy and T-cell engaging bispecific antibodies (BsAbs) have fundamentally altered the...
Chimeric antigen receptor T-cell (CAR T) therapy stands as one of the most remarkable breakthroughs in modern oncology. By genetically...
Executive Overview Cutaneous T-cell lymphomas (CTCLs) represent a complex and heterogeneous family of clonal lymphoproliferative disorders originating from skin-homing T...
Executive Overview Acute lymphoblastic leukemia (ALL) remains the most prevalent pediatric malignancy globally, yet a profound geopolitical divide continues to...
Executive Overview Acute promyelocytic leukemia (APL) has long been considered one of the great success stories of modern hematology, with...
Executive Overview For more than half a century, cytotoxic chemotherapy has achieved a monumental milestone in modern medicine: the routine,...
Executive Overview For decades, disease relapse following an allogeneic hematopoietic cell transplantation (allo-HCT)—the high-stakes curative procedure for acute leukemias and...
Executive Overview When a patient receives a leukaemia diagnosis, the shockwaves instantly reverberate far beyond hospital walls, profoundly altering the...
In a rare and clinically complex case highlighting the hidden dangers of cancer-associated coagulopathy, medical specialists at Padua University Hospital...
Executive Overview Acute Myeloid Leukemia (AML) is one of the most aggressive and complex malignancies of the human hematopoietic system....
Executive Overview Red blood cells (RBCs) rely entirely on glycolysis to sustain their structural integrity, membrane flexibility, and essential physiological...